MRI-targeted prostate biopsy: the next step forward

• Published in: Medicine and pharmacy reports Vol. 94; no. 2; pp. 145 - 157
• Main Authors: Cata, Emanuel Darius, Andras, Iulia, Telecan, Teodora, Tamas-Szora, Attila, Coman, Radu-Tudor, Stanca, Dan-Vasile, Coman, Ioan, Crisan, Nicolae
• Format: Journal Article
• Language: English
• Published: Romania Iuliu Hatieganu University of Medicine and Pharmacy 01.04.2021
• Subjects: Review: Urology; multiparametric MRI; In-Bore MRI targeted biopsy; Fusion targeted biopsy; prostate cancer detection; systematic prostate biopsy; targeted prostate biopsy
• ISSN: 2602-0807; 2668-0572
• DOI: 10.15386/mpr-1784

For decades, the gold standard technique for diagnosing prostate cancer was the 10 to 12 core systematic transrectal or transperineal biopsy, under ultrasound guidance. Over the past years, an increased rate of false negative results and detection of clinically insignificant prostate cancer has been noted, resulting into overdiagnosis and overtreatment. The purpose of the current study was to evaluate the changes in diagnosis and management of prostate cancer brought by MRI-targeted prostate biopsy. A critical review of literature was carried out using the Medline database through a PubMed search, 37 studies meeting the inclusion criteria: prospective studies published in the past 8 years with at least 100 patients per study, which used multiparametric magnetic resonance imaging as guidance for targeted biopsies. In-Bore MRI targeted biopsy and Fusion targeted biopsy outperform standard systematic biopsy both in terms of overall and clinically significant prostate cancer detection, and ensure a lower detection rate of insignificant prostate cancer, with fewer cores needed. In-Bore MRI targeted biopsy performs better than Fusion biopsy especially in cases of apical lesions. Targeted biopsy is an emerging and developing technique which offers the needed improvements in diagnosing clinically significant prostate cancer and lowers the incidence of insignificant ones, providing a more accurate selection of the patients for active surveillance and focal therapies.